Non-alcoholic Steatohepatitis Therapeutics And Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Non-alcoholic Steatohepatitis Therapeutics And Diagnostics Market Trends and Insights

Rising Prevalence of Obesity & Metabolic Syndrome

Obesity and metabolic dysfunction now affect close to one-third of the global population, creating an expanding clinical pool for MASLD and, by progression, nonalcoholic steatohepatitis. The demographic tilt toward younger cohorts accelerates fibrosis at earlier ages and stretches lifetime treatment windows. Latin America illustrates the trend as prevalence nears 24%, driving payer interest in community-level screening programs. U.S. projections indicate 27 million affected adults by 2030, a 63% jump versus 2015, redefining transplant-planning models and stimulating commercial urgency. Governments and professional societies respond by integrating fibrosis scores into primary-care check-ups, further enlarging addressable volumes for both diagnostics and therapeutics.

Advancement in Non-Invasive Diagnostic Technologies

Market momentum pivots around rapid adoption of blood-based panels and elastography that replace invasive liver biopsy. Roche’s Elecsys PRO-C3 returns fibrosis staging in 18 minutes, enabling same-visit clinical decisions and widening provider acceptance. AI algorithms now mine electronic health records to flag undiagnosed MASLD with 83% accuracy, adding scale without incremental imaging capacity. FibroScan, ELF, and FIB-4 scores are embedded in new treatment guidelines across the U.S. and Europe, prompting laboratories to upgrade equipment portfolios. Earlier detection increases therapeutic eligibility pools and underpins value-based reimbursement arguments that emphasize avoided transplant costs.

Payer Willingness to Reimburse Biomarker Tests

Commercial insurers increasingly reimburse ELF and NIS4 panels once linked to reduced downstream expenditures. Labcorp’s NASHnext™ secured broad coverage in early 2024, signalling payer readiness to reward diagnostics that avert high-cost cirrhosis care. Medicare’s 2025 National Coverage Determination for non-invasive fibrosis testing further normalizes reimbursement pathways. Europe follows with country-level health technology assessments validating clinical utility. The resulting financial clarity encourages diagnostic-centric startups to scale distribution and accelerates hospital procurement of elastography devices.

Combination-Therapy Pipeline Expansion

Clinical rationale for multi-target regimens strengthens as monotherapies struggle to deliver dual endpoints of fibrosis improvement and NASH resolution. Novo Nordisk’s GLP-1 plus FXR agonist research and Gilead’s paired FGF21 analogue strategy widen therapeutic possibilities without requiring de-novo modes of action. Combination paradigms appeal to regulators when mechanistic synergy addresses heterogeneity in disease pathways, motivating collaborative trials and intellectual-property cross-licensing. Successful proof-of-concept data would expand addressable market value by enabling tailored regimens across fibrosis stages.

High Late-Stage Drug-Trial Failure Rate

Historical attrition has eroded investor sentiment each time a promising candidate underperformed in Phase 2b or Phase 3. Akero’s efruxifermin missed key fibrosis endpoints with response rates of 18–29% versus 13% placebo, reviving concerns over surrogate markers versus hard histological outcomes. Companies react by tightening inclusion criteria, but smaller sample sizes raise statistical-power questions that regulators scrutinize. The cyclical pattern of hype and disappointment elongates development timelines, tempers deal valuations, and moderates the Nonalcoholic Steatohepatitis therapeutics and diagnostics market growth curve despite headline breakthroughs.

Uncertain Reimbursement for Novel Diagnostics

Emerging AI and multi-omic panels confront fragmented payer frameworks, especially in Latin America and parts of Asia where public budgets prioritize primary care. Health technology assessment agencies demand longitudinal outcome data, lengthening approval cycles beyond what venture-backed diagnostic firms can often fund. Europe’s differential acceptance benches novel panels against well-established FIB-4 or FibroScan, forcing companies to conduct added head-to-head studies. Until consistent coverage materializes, adoption curves in cost-sensitive regions remain shallow, partially offsetting growth elsewhere.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Solution: Therapeutics Drive Future Growth Despite Diagnostic Dominance

Diagnostics retained 59.85% revenue share in 2025 on the strength of widespread use of elastography and blood-based panels across primary and secondary care sites. Nevertheless, therapeutics exhibit the fastest momentum, expanding at a 19.11% CAGR, powered initially by resmetirom’s launch. Within the solution stack, imaging tests and biomarker assays continue to diversify, while biopsy volumes contract as clinicians shift to guideline-endorsed non-invasive monitoring. Resmetirom generated USD 137 million in Q1 2025 alone, proving willingness to pay even at an annual USD 47,400 price point. Pipeline depth in GLP-1, THR-β, and FGF21 classes suggests sustained innovation cycles that can progressively narrow fibrosis progression rates.

Expanded therapeutic access is expected to rebalance spending patterns such that therapeutics account for the larger share of the nonalcoholic Steatohepatitis therapeutics and diagnostics market size by late-decade. The current gap between diagnosis and treatment adoption generates pent-up demand suited to first-in-class entrants. Diagnostics still accrue steady transactional revenue from repeat fibrosis monitoring; however, growth rates taper as market saturation rises in high-income countries. Technology suppliers pivot to value-added analytics and longitudinal patient-management platforms to protect margins. Multimodal diagnostic algorithms that integrate imaging, serum biomarkers, and electronic health record data differentiate service offerings and lock-in provider relationships.

By End User: Diagnostic Centers Emerge as Growth Leaders

Hospitals and clinics generated 44.52% of Nonalcoholic Steatohepatitis therapeutics and diagnostics market revenue in 2025, reflecting entrenched referral pathways and bundled billing practices. Yet diagnostic centers are tracking an 18.42% CAGR, outpacing all other settings as patients gravitate toward convenience and shorter appointment backlogs. Urban Asia-Pacific illustrates the shift, where standalone imaging chains add dedicated liver units supported by AI-enabled interpretation and cloud-based reporting. Academic institutes continue to shape clinical guidelines and attract early-stage trials, making them critical gatekeepers for technology validation.

Integration between diagnostic centers and hepatology specialists accelerates care coordination, leading to higher therapy conversion rates. Telehealth follow-up, remote FibroScan vans, and mobile phlebotomy further erode hospital dominance for routine monitoring. For providers, profitability hinges on high throughput and pay-for-performance contracts that reward early disease interception.

Geography Analysis

North America retained its 36.78% revenue lead in 2025, underpinned by early regulatory approvals, broad insurance coverage, and high obesity prevalence. U.S. hepatologists rapidly incorporated resmetirom into practice after March 2024 approval, elevating prescription volumes even before full guideline integration. Canada mirrors trends on a smaller scale, benefitting from centralized health-technology assessments that green-light non-invasive diagnostics for provincial coverage. The region’s innovation ecosystem, anchored by Boston and San Diego biotech clusters, ensures a continual influx of trial candidates and venture capital, reinforcing first-mover advantages in therapeutics and AI-powered diagnostics.

Europe contributes steady, mid-teen revenue shares with Germany, the United Kingdom, and France accounting for the bulk of uptake. EMA approval of resmetirom, anticipated mid-2025, will unlock pent-up demand. National reimbursement agencies are already modeling budget impacts, suggesting quicker formulary listings than seen with earlier metabolic drugs. Non-invasive diagnostic penetration is mature, yet opportunities remain in integrating AI-triaged imaging into regional liver networks to tackle workforce shortages. Parallel import regulations may exert mild downward pressure on launch prices, but volume growth is expected to compensate.

Asia-Pacific is the fastest-growing theatre, set to surge at a 18.67% CAGR as diabetes and obesity climb across China, India, and Southeast Asia. Multinational companies localize clinical trials to satisfy diverse ethnic profiles and streamline China’s National Medical Products Administration approvals. Madrigal’s July 2025 USD 2 billion licensing pact with CSPC exemplifies route-to-market strategies that combine local manufacturing with multinational science. Government prevention programs and growing middle-class awareness enlarge screening volumes for fibrosis tests. Australia and South Korea, with advanced reimbursement systems, act as gateway markets for new diagnostics before broader regional rollout.

South America and the Middle East & Africa collectively represent nascent but rising prospects. Brazil’s public-private hospital model experiments with capitated payments that reward early fibrosis detection. GCC nations invest in specialty liver centers, leveraging high per-capita health spending to adopt latest diagnostics. However, reimbursement fragmentation and workforce imbalances temper near-term gains, keeping their combined share in single digits through 2031.

Regulatory Landscape

Regulation in nonalcoholic steatohepatitis (MASH/NASH) therapeutics and diagnostics is increasingly shaped by accelerated and conditional approval pathways for drugs, alongside qualification routes for trial endpoints and tools. In the United States, the FDA granted accelerated approval to resmetirom in March 2024, and in August 2025 the FDA accepted a letter of intent to qualify vibration-controlled transient elastography (VCTE) as a reasonably likely surrogate endpoint for adult MASH trials with moderate-to-advanced fibrosis. In Europe, the EMA advanced GLP-1-based therapy access with a CHMP positive opinion in January 2026, followed by EU conditional marketing authorization in March 2026 for Kayshild (semaglutide) in non-cirrhotic MASH with moderate-to-advanced fibrosis.

Regulators are also formalizing digital pathology and AI within development programs, tightening expectations for analytical validity and reproducibility. The EMA issued a Qualification Opinion for the AIM-NASH AI tool in March 2025 for analysis of liver biopsy scans, and the FDA later qualified AIM-NASH under its Drug Development Tool program in December 2025, reinforcing a regulatory pathway for algorithm-supported histology reads in pivotal trials. For device-drug combinations and software-enabled diagnostics, the Primary Mode of Action framework in the US (for example, CDER vs CDRH lead review) and EU Medical Device Regulation requirements, including Notified Body involvement for certain combinations, remain central to planning evidence packages, labeling, and market access sequencing.

Value Chain Analysis

The value chain spans discovery and clinical development of therapeutics (biopharma sponsors, CRO networks, and trial sites), alongside diagnostic R&D and manufacturing (assay developers, imaging and elastography OEMs, and software/AI vendors), culminating in clinical delivery through hospitals, diagnostic centers, and large laboratory networks. A key inflection is the tighter coupling of diagnostics with drug development, shown by Echosens expanding its collaboration with Boehringer Ingelheim in June 2025 to embed FibroScan screening and monitoring into Survodutide Phase III trials, and by Echosens receiving FDA CDER acceptance in September 2025 of its Letter of Intent to qualify FibroScan liver stiffness measurement as a surrogate endpoint for MASH trials. These moves push demand upstream toward standardized, scalable non-invasive tests that can recruit, stratify, and monitor trial populations while reducing reliance on biopsy logistics.

Downstream commercialization is increasingly driven by partnerships that provide distribution scale, clinical adoption, and reimbursement execution. In diagnostics, GENFIT launched NASHnext (powered by NIS4) via Labcorp OnDemand in June 2026 to broaden access to at-risk MASH identification, and it subsequently announced US Medicare coverage with reimbursement scheduled from August 10, 2026, reinforcing the payer-to-provider link that supports recurring testing volumes. Capability-building alliances also extend AI-enabled diagnostic services at clinical sites, such as HistoIndex partnering with Houston Research Institute in January 2026 to deploy AI-based FibroSIGHT Plus testing across multiple centers, where algorithm validation, laboratory operations, and reimbursement strategy increasingly shape time-to-scale.

Market Opportunities and Future Outlook

A gap persists between high diagnostic detection volumes and conversion into therapy initiation, creating opportunity for integrated care pathways that combine non-invasive staging, longitudinal monitoring, and payer-aligned treatment criteria. Recent regulatory and reimbursement signals support this integration, including the FDA accepting a proposal tied to reasonably likely surrogate endpoints for MASH-related clinical outcomes, and progressing non-invasive surrogate endpoint qualification activity around VCTE. Medicare coverage actions have also expanded access to non-invasive fibrosis and biomarker testing. Together, these steps reduce friction for diagnostic centers and laboratories to embed fibrosis risk stratification into routine workflows, particularly when combined with same-visit tools such as rapid biomarker assays and scalable ordering models like direct-to-lab channels.

Therapeutics commercialization is broadening beyond the first THR-beta approval into additional mechanism classes and geographies, creating room for companion diagnostics, combination regimens, and differentiated patient segmentation by fibrosis stage. In addition to resmetirom's March 2024 FDA approval, semaglutide received EU conditional marketing authorization in March 2026 for non-cirrhotic MASH with moderate-to-advanced fibrosis, and the UK MHRA granted conditional marketing authorization in July 2026, expanding the set of reimbursable treatment pathways and increasing the need for standardized non-invasive monitoring. Pipeline investment also points to modality expansion beyond small molecules, with Madrigal announcing in February 2026 an exclusive global licensing agreement covering six preclinical siRNA programs intended to expand its MASH pipeline. This reinforces demand for biomarker strategies capable of tracking mechanism-specific response and supporting differentiated labeling claims.